Septerna: A De-Risking GPCR Story With Near-Term Upside Catalysts
Septerna (SEPN) stock: strong balance sheet, funded to 2029, and near-term clinical catalysts (SEP-631, SEP-479). See more details here.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4915552-septerna-a-de-risking-gpcr-story-with-near-term-upside-catalysts"},"author":{"@type":"Person","name":"Petri Dish Reports","url":"https://seekingalpha.com/author/petri-dish-reports"},"publisher":{"@context":"https://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
